Lenalidomide and dexamethasone for multiple myeloma

Research output: Contribution to journalArticle

Abstract

Patients with smouldering or asymptomatic multiple myeloma (SMM) are not treated until symptomatic disease develops. SMM is characterised by a serum monoclonal protein component of 3 g/dL or plasma cell infiltration into bone marrow of 10% or more.
Original languageEnglish
Pages (from-to)240-241
Number of pages2
JournalJournal of Pharmacy Practice and Research
Volume43
Issue number3
Publication statusPublished - 2013

Fingerprint

Plasma Cells
Multiple Myeloma
Dexamethasone
Bone
Bone Marrow
Plasmas
Serum
lenalidomide

Cite this

@article{3407515017444dd5aaa5d47e3cab07fc,
title = "Lenalidomide and dexamethasone for multiple myeloma",
abstract = "Patients with smouldering or asymptomatic multiple myeloma (SMM) are not treated until symptomatic disease develops. SMM is characterised by a serum monoclonal protein component of 3 g/dL or plasma cell infiltration into bone marrow of 10{\%} or more.",
keywords = "asymptomatic multiple myeloma, SMM, bone marrow, blood pressure",
author = "Mark NAUNTON",
year = "2013",
language = "English",
volume = "43",
pages = "240--241",
journal = "Australian Journal of Hospital Pharmacy",
issn = "0310-6810",
publisher = "Wiley-Blackwell",
number = "3",

}

Lenalidomide and dexamethasone for multiple myeloma. / NAUNTON, Mark.

In: Journal of Pharmacy Practice and Research, Vol. 43, No. 3, 2013, p. 240-241.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lenalidomide and dexamethasone for multiple myeloma

AU - NAUNTON, Mark

PY - 2013

Y1 - 2013

N2 - Patients with smouldering or asymptomatic multiple myeloma (SMM) are not treated until symptomatic disease develops. SMM is characterised by a serum monoclonal protein component of 3 g/dL or plasma cell infiltration into bone marrow of 10% or more.

AB - Patients with smouldering or asymptomatic multiple myeloma (SMM) are not treated until symptomatic disease develops. SMM is characterised by a serum monoclonal protein component of 3 g/dL or plasma cell infiltration into bone marrow of 10% or more.

KW - asymptomatic multiple myeloma

KW - SMM

KW - bone marrow

KW - blood pressure

M3 - Article

VL - 43

SP - 240

EP - 241

JO - Australian Journal of Hospital Pharmacy

JF - Australian Journal of Hospital Pharmacy

SN - 0310-6810

IS - 3

ER -